Jaxteran

Dimethyl fumarate, the active ingredient in Jaxteran, is an immunomodulator presented as an oral formulation for oral use. It is indicated for relapsing forms of multiple sclerosis and for moderate-to-severe plaque psoriasis in adult patients effectively.

GNH USA supplies Jaxteran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured product availability for qualified healthcare providers. The company adheres to EU GMP standards and provides regulatory documentation to support import and distribution across multiple regions.

Dimethyl fumarate is employed in immune‑mediated conditions, targeting disease activity in both the central nervous system and the skin, thereby modifying relapse rates and lesion development.

- Relapsing multiple sclerosis: reduces the frequency of clinical relapses and may slow accumulation of disability. - Moderate-to-severe plaque psoriasis: improves skin lesion clearance and decreases disease severity scores.

Dimethyl fumarate is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Flushing: transient warmth and redness, often occurring after the first doses. - Gastrointestinal discomfort: nausea, abdominal pain, or diarrhoea. - Upper respiratory tract symptoms: nasopharyngitis or sore throat. - Decreased lymphocyte count: mild reductions observed in routine blood tests.

Serious or Rare Side Effects: - Progressive multifocal leukoencephalopathy (PML): rare opportunistic brain infection. - Severe hypersensitivity reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing dimethyl fumarate, clinicians should consider several precautionary measures to minimize risk.

- Baseline monitoring: obtain complete blood count and liver function tests before initiating therapy. - Infection risk: assess for active infections and avoid use in patients with known immunosuppression. - Pregnancy: avoid use during pregnancy unless potential benefit justifies risk, as safety data are limited. - Vaccination: administer necessary vaccines prior to treatment initiation. - Renal or hepatic impairment: use with caution and monitor organ function regularly. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Dimethyl fumarate may interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid): - Live vaccines: concurrent use can increase risk of vaccine‑derived infection. - Immunosuppressants: combined therapy may heighten infection risk.

Moderate Interactions (Monitor Closely): - Antioxidant supplements (e.g., vitamin C, E): may attenuate Nrf2 activation. - CYP450 substrates: dimethyl fumarate can modestly influence metabolism of drugs processed by CYP enzymes. - Anticoagulants: monitor for altered bleeding risk due to potential platelet effects.